IUL Stock Overview
An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ImmuCell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.46 |
| 52 Week High | US$4.98 |
| 52 Week Low | US$3.10 |
| Beta | 0.57 |
| 11 Month Change | 6.14% |
| 3 Month Change | 8.13% |
| 1 Year Change | -19.91% |
| 33 Year Change | -57.28% |
| 5 Year Change | -22.77% |
| Change since IPO | -45.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| IUL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -0.2% | 0.8% |
| 1Y | -19.9% | -16.9% | 9.1% |
Return vs Industry: IUL underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: IUL underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| IUL volatility | |
|---|---|
| IUL Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IUL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IUL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 78 | Michael Brigham | immucell.com |
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
ImmuCell Corporation Fundamentals Summary
| IUL fundamental statistics | |
|---|---|
| Market cap | €27.54m |
| Earnings (TTM) | -€3.63m |
| Revenue (TTM) | €22.71m |
1.2x
P/S Ratio-7.7x
P/E RatioIs IUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IUL income statement (TTM) | |
|---|---|
| Revenue | US$23.84m |
| Cost of Revenue | US$16.94m |
| Gross Profit | US$6.89m |
| Other Expenses | US$10.71m |
| Earnings | -US$3.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 28.92% |
| Net Profit Margin | -15.99% |
| Debt/Equity Ratio | 41.3% |
How did IUL perform over the long term?
See historical performance and comparison